Materials for Immunotherapy
- PMID: 31250498
- DOI: 10.1002/adma.201901633
Materials for Immunotherapy
Abstract
Breakthroughs in materials engineering have accelerated the progress of immunotherapy in preclinical studies. The interplay of chemistry and materials has resulted in improved loading, targeting, and release of immunomodulatory agents. An overview of the materials that are used to enable or improve the success of immunotherapies in preclinical studies is presented, from immunosuppressive to proinflammatory strategies, with particular emphasis on technologies poised for clinical translation. The materials are organized based on their characteristic length scale, whereby the enabling feature of each technology is organized by the structure of that material. For example, the mechanisms by which i) nanoscale materials can improve targeting and infiltration of immunomodulatory payloads into tissues and cells, ii) microscale materials can facilitate cell-mediated transport and serve as artificial antigen-presenting cells, and iii) macroscale materials can form the basis of artificial microenvironments to promote cell infiltration and reprogramming are discussed. As a step toward establishing a set of design rules for future immunotherapies, materials that intrinsically activate or suppress the immune system are reviewed. Finally, a brief outlook on the trajectory of these systems and how they may be improved to address unsolved challenges in cancer, infectious diseases, and autoimmunity is presented.
Keywords: controlled release; drug delivery; immunotherapy; materials engineering; personalized medicine.
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Similar articles
-
Combining Nanomedicine and Immunotherapy.Acc Chem Res. 2019 Jun 18;52(6):1543-1554. doi: 10.1021/acs.accounts.9b00148. Epub 2019 May 23. Acc Chem Res. 2019. PMID: 31120725 Free PMC article.
-
Delivery strategies of cancer immunotherapy: recent advances and future perspectives.J Hematol Oncol. 2019 Nov 28;12(1):126. doi: 10.1186/s13045-019-0817-3. J Hematol Oncol. 2019. PMID: 31779642 Free PMC article. Review.
-
A brief glimpse over the horizon for type 1 diabetes nanotherapeutics.Clin Immunol. 2015 Sep;160(1):36-45. doi: 10.1016/j.clim.2015.03.016. Epub 2015 Mar 25. Clin Immunol. 2015. PMID: 25817545 Review.
-
Antibody-targeted nanoparticles for cancer therapy.Immunotherapy. 2011 Mar;3(3):381-94. doi: 10.2217/imt.11.5. Immunotherapy. 2011. PMID: 21395380 Review.
-
Nanotechnology-based products for cancer immunotherapy.Mol Biol Rep. 2022 Feb;49(2):1389-1412. doi: 10.1007/s11033-021-06876-y. Epub 2021 Oct 29. Mol Biol Rep. 2022. PMID: 34716502 Free PMC article. Review.
Cited by
-
A Zinc- and Calcium-Rich Lysosomal Nanoreactor Rescues Monocyte/Macrophage Dysfunction under Sepsis.Adv Sci (Weinh). 2023 Feb;10(6):e2205097. doi: 10.1002/advs.202205097. Epub 2023 Jan 3. Adv Sci (Weinh). 2023. PMID: 36596693 Free PMC article.
-
Rational Vaccinology: Harnessing Nanoscale Chemical Design for Cancer Immunotherapy.ACS Cent Sci. 2022 Jun 22;8(6):692-704. doi: 10.1021/acscentsci.2c00227. Epub 2022 May 20. ACS Cent Sci. 2022. PMID: 35756370 Free PMC article. Review.
-
Cellular backpacks for macrophage immunotherapy.Sci Adv. 2020 Apr 29;6(18):eaaz6579. doi: 10.1126/sciadv.aaz6579. eCollection 2020 May. Sci Adv. 2020. PMID: 32494680 Free PMC article.
-
Magnetic systems for cancer immunotherapy.Acta Pharm Sin B. 2021 Aug;11(8):2172-2196. doi: 10.1016/j.apsb.2021.03.023. Epub 2021 Apr 30. Acta Pharm Sin B. 2021. PMID: 34522583 Free PMC article. Review.
-
Agent-Based Modeling of Virtual Tumors Reveals the Critical Influence of Microenvironmental Complexity on Immunotherapy Efficacy.Cancers (Basel). 2024 Aug 23;16(17):2942. doi: 10.3390/cancers16172942. Cancers (Basel). 2024. PMID: 39272799 Free PMC article.
References
-
- a) L. Milling, Y. Zhang, D. J. Irvine, Adv. Drug Delivery Rev. 2017, 114, 79;
-
- b) M. L. Bookstaver, S. J. Tsai, J. S. Bromberg, C. M. Jewell, Trends Immunol. 2018, 39, 135;
-
- c) R. S. Riley, C. H. June, R. Langer, M. J. Mitchell, Nat. Rev. Drug Discovery 2019.
-
- J. O’Donnell-Tormey, Timeline of Progress in Immunotherapy- Cancer Research Institute, https://www.cancerresearch.org/immunotherapy/timeline-of-progress, (accessed: June 2019).
-
- a) A. S. Timin, M. M. Litvak, D. A. Gorin, E. N. Atochina-Vasserman, D. N. Atochin, G. B. Sukhorukov, Adv. Healthcare Mater. 2018, 7, 1700818;
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials